Fig. 6: G4 ligand TMPyP4 enhances antitumor responses induced by anti-PD1. | Cell Death & Disease

Fig. 6: G4 ligand TMPyP4 enhances antitumor responses induced by anti-PD1.

From: Targeting G-quadruplex by TMPyP4 for inhibition of colorectal cancer through cell cycle arrest and boosting anti-tumor immunity

Fig. 6: G4 ligand TMPyP4 enhances antitumor responses induced by anti-PD1.The alternative text for this image may have been generated using AI.

a–f Tumor growth of vehicle, TMPyP4 alone (30 mg/kg), anti-PD1 alone (200 μg/body), and TMPyP4 plus anti-PD1 groups in BALB/C mice injected with CT26 cells (a–c) or C57BL/C mice injected with MC38 cells (d–f). n = 4 mice for each group. g, h The frequencies of CD8+ T cells in CT26 (g) and MC38 (h) tumors after vehicle, TMPyP4 alone (30 mg/kg), anti-PD1 alone (200 μg/body), and TMPyP4 plus anti-PD1 groups treatment. Values are represented as mean ± SD, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, by two-way ANOVA (b, e), or by untailed t-tests (c, f, g, h). i Relationship between G4 expression and immunotherapy efficacy in colorectal patients. j The overview of the study.

Back to article page